SynthesisFrontiers in nephrology2026
Efficacy and safety of vitamin D supplementation in diabetic kidney disease: an umbrella review of systematic reviews and meta-analyses.
Synthesis in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD), including classical diabetic nephropathy, is a leading cause of chronic kidney disease and kidney replacement therapy. Vitamin D supplementation has been proposed to reduce albuminuria, but the available reviews are heterogeneous and redundant. Objective: To critically evaluate and summarize the efficacy and safety of native vitamin D and active vitamin D analogs in adults with DKD, including studies reported as diabetic nephropathy (DN). Methods: An overview of reviews registered in PROSPERO (CRD420251250914). Systematic reviews, with or without meta-analysis, were searched in MEDLINE/PubMed, Embase, the Cochrane Library, Web of Science, and Scopus, without language restrictions, through April 2, 2026. Methodological quality was assessed with AMSTAR-2, risk of bias with ROBIS, overlap with Corrected Covered Area (CCA), and certainty of evidence with GRADE. The synthesis used one anchor review per outcome, without Results: Eleven reviews met the eligibility criteria; nine provided evidence derived from randomized trials or separable randomized-trial data, and two were retained as contextual evidence. GRADE certainty was low for the surrogate urinary outcomes UACR and UAER, low to very low for 24-hour proteinuria, and very low or not evaluable for renal function, kidney replacement therapy, mortality, cardiovascular events, safety, and metabolic-inflammatory outcomes. Overlap was high (overall CCA, 13.5%; RCT-derived corpus, 14.1%). The evidence was compatible with low-certainty reductions in surrogate urinary outcomes, especially UACR and UAER, without consistent benefit for eGFR, serum creatinine, kidney replacement therapy, mortality, or cardiovascular events; safety was insufficiently reported. Conclusions: Vitamin D shows a low-certainty reduction in surrogate urinary markers of albuminuria/proteinuria in DKD, but current evidence is insufficient to support vitamin D as a specific renoprotective intervention beyond conventional indications for deficiency or mineral and bone disorders. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251250914, identifier CRD420251250914.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.